1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lineage deconvolution using chromatin accessibility and DNA methylation shows a spectrum of lineage characteristics and differentiation states across acute leukemias
    Meeting Abstract

    Glass, J. L.; Palia, A. J.; Garrett-Bakelman, F. E.; Koche, R.; Levine, R. L.; Tallman, M. S.; Dillon, R. J.; Grimwade, D.; Ferrando, A. A.; Valk, P. J. M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Natural history of hypogammaglobulinemia in patients with follicular lymphoma and the impact of anti-CD20-based therapy
    Meeting Abstract

    Fischer, T.; Ni, A.; Soumerai, J. D.; Alperovich, A.; Batlevi, C. L.; Younes, A.; Zelenetz, A. D.
    Blood (2017)

    Fulltext@MSK | Save
  • Prospective study of acute myeloid leukemia (AML) clinical epidemiology and cytogenetic risk group in older adults in the ECOG-ACRIN E2906 clinical trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) study
    Meeting Abstract

    Foran, J. M.; Zhang, Y.; Heckman, M.; Luger, S.; Hulshizer, C.; Vargas, E.; Litzow, M. R.; Altman, J. K.; Pratz, K.; Mattison, R.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Generation and application of T-cell lymphoma patient derived tumor xenograft models
    Meeting Abstract

    Fiore, D.; Wang, X.; Khodos, I.; Di Giacomo, F.; Gaudiano, M.; Phillip, J. M.; Wang, R.; Yang, Z.; Ginsberg, M.; Intlekofer, A. M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A phase 2 study of actinium-225 ((225)Ac)-lintuzumab in older patients with previously untreated acute myeloid leukemia (AML) unfit for intensive chemotherapy
    Meeting Abstract

    Finn, L. E.; Levy, M.; Orozco, J. J.; Park, J. H.; Atallah, E.; Craig, M.; Perl, A. E.; Scheinberg, D. A.; Cicic, D.; Bergonio, G. R.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Dot1l reverses the abnormal self-renewal conferred on HSPCs through cohesin haploinsufficiency by diminishing expression of Hoxa7 and Hoxa9
    Meeting Abstract

    Fisher, J. B.; Stelloh, C.; Phillips, E. K.; Heimbruch, K.; Meyer, A. E.; Pulakanti, K.; McNulty, M.; Viny, A. D.; Levine, R. L.; Crispino, J. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Maximum tolerated dose (MTD) and safety profile from phase I study of MT-3724 (CD20 targeted immunotoxin) in relapsed/refractory (R/R) non-Hodgkin B-cell lymphoma (NHL)
    Meeting Abstract

    Fanale, M. A.; Park, S. I.; Valacer, D. J.; Higgins, J.; Sloan, J. M.; Younes, A.; Hamlin, P. A.
    Blood (2017)

    Fulltext@MSK | Save
  • Five-year survival results: Frontline brentuximab vedotin in combination with CHP in patients with CD30-expressing peripheral T-cell lymphomas
    Meeting Abstract

    Fanale, M. A.; Horwitz, S. M.; Forero-Torres, A.; Bartlett, N. L.; Advani, R. H.; Pro, B.; Chen, R. W.; Davies, A.; Illidge, T. M.; Uttarwar, M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A cost-benefit analysis of bortezomib, lenalidomide, and bortezomib/lenalidomide combination therapy for newly diagnosed multiple myeloma
    Meeting Abstract

    Fiala, M. A.; Wildes, T. M.; Shah, G. L.; Ghobadi, A.; Schroeder, M. A.; Stockerl-Goldstein, K. E.; Vij, R.
    Blood (2017)

    Fulltext@MSK | Save
  • Sequential brentuximab vedotin (Bv) before and after adriamycin, vinblastine, and dacarbazine (Bv-AVD) for older patients with untreated classical Hodgkin lymphoma (cHL): Final results from a multicenter phase II study
    Meeting Abstract

    Evens, A. M.; Advani, R. H.; Fanale, M. A.; Smith, S. M.; Helenowski, I.; Jovanovic, B.; Bociek, R. G.; Klein, A.; Winter, J. N.; Gordon, L. I.; more...
    Blood (2017)

    Fulltext@MSK | Save